ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for charts 실시간 차트, 분석 도구 및 가격을 받으려면 등록하세요.
Verve Therapeutics Inc

Verve Therapeutics Inc (VERV)

8.58
0.87
(11.28%)
마감 17 2월 6:00AM
8.60
0.02
(0.23%)
시간외 거래: 9:44AM

실시간 토론 및 거래 아이디어: 강력한 플랫폼으로 자신있게 거래하세요.

주요 통계 및 세부정보

가격
8.60
매수가
8.38
매도가
8.80
거래량
1,408,477
7.82 일간 변동폭 8.87
4.305 52주 범위 19.34
market_cap
전일 종가
7.71
개장가
7.82
최근 거래 시간
60
@
8.8
마지막 거래 시간
재정 규모
US$ 11,960,538
VWAP
8.4918
평균 볼륨(3m)
1,540,623
발행 주식
84,663,840
배당수익률
-
주가수익률
-3.63
주당순이익(EPS)
-2.36
매출
11.76M
순이익
-200.07M

Verve Therapeutics Inc 정보

Verve Therapeutics Inc is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company's initial two programs target PCSK9 and ANGPTL3, genes that have been extensively... Verve Therapeutics Inc is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company's initial two programs target PCSK9 and ANGPTL3, genes that have been extensively validated as targets for lowering blood lipids such as low-density lipoprotein cholesterol, a root cause of cardiovascular disease. The company views its operations as and manages its business in one operating segment operating exclusively in the United States. 더 보기

섹터
Pharmaceutical Preparations
산업
Pharmaceutical Preparations
웹사이트
본부
Wilmington, Delaware, USA
설립됨
-
Verve Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the 나스닥 with ticker VERV. The last closing price for Verve Therapeutics was US$7.71. Over the last year, Verve Therapeutics shares have traded in a share price range of US$ 4.305 to US$ 19.34.

Verve Therapeutics currently has 84,663,840 shares in issue. The market capitalisation of Verve Therapeutics is US$652.76 million. Verve Therapeutics has a price to earnings ratio (PE ratio) of -3.63.

VERV 최신 뉴스

기간변동변동 %시가고가저가평균 일일 거래량VWAP
10.151.775147928998.458.637.4410676337.94242149CS
42.4940.75286415716.118.776.09515971817.68373388CS
124.0890.26548672574.528.774.5115406236.58758774CS
264.0187.36383442274.598.774.30514779585.93865787CS
52-4-31.74603174612.619.344.30514079526.96157821CS
156-22.46-72.311654861631.06434.305109636914.19604351CS
260-21.4-71.333333333330784.30598621816.8892171CS

VERV - Frequently Asked Questions (FAQ)

What is the current Verve Therapeutics share price?
The current share price of Verve Therapeutics is US$ 8.60
How many Verve Therapeutics shares are in issue?
Verve Therapeutics has 84,663,840 shares in issue
What is the market cap of Verve Therapeutics?
The market capitalisation of Verve Therapeutics is USD 652.76M
What is the 1 year trading range for Verve Therapeutics share price?
Verve Therapeutics has traded in the range of US$ 4.305 to US$ 19.34 during the past year
What is the PE ratio of Verve Therapeutics?
The price to earnings ratio of Verve Therapeutics is -3.63
What is the cash to sales ratio of Verve Therapeutics?
The cash to sales ratio of Verve Therapeutics is 61.77
What is the reporting currency for Verve Therapeutics?
Verve Therapeutics reports financial results in USD
What is the latest annual turnover for Verve Therapeutics?
The latest annual turnover of Verve Therapeutics is USD 11.76M
What is the latest annual profit for Verve Therapeutics?
The latest annual profit of Verve Therapeutics is USD -200.07M
What is the registered address of Verve Therapeutics?
The registered address for Verve Therapeutics is CORPORATION TRUST CENTER, 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
What is the Verve Therapeutics website address?
The website address for Verve Therapeutics is www.vervetx.com
Which industry sector does Verve Therapeutics operate in?
Verve Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

이동자

모두 보기
  • 가장 활성
  • % 상승자
  • % 패자
기호가격볼륨
JTAIJet AI Inc
US$ 6.02
(133.33%)
104.48M
SRMSRM Entertainment Inc
US$ 0.6999
(95.50%)
254.39M
WRDWeRide Inc
US$ 31.4877
(83.39%)
21.07M
INLFINLIF Limited
US$ 16.27
(80.58%)
7.68M
MBRXMoleculin Biotech Inc
US$ 2.1201
(66.94%)
136.66M
BLACBellevue Life Sciences Acquisition Corporation
US$ 3.08
(-56.31%)
430.77k
BLACUBellevue Life Sciences Acquisition Corporation
US$ 3.36
(-52.68%)
5.21k
CSAICloudastructure Inc
US$ 19.0001
(-49.58%)
1.03M
NEXNNexxen International Ltd
US$ 10.30
(-49.16%)
164.82k
BSLKBolt Projects Holdings Inc
US$ 0.6626
(-46.13%)
13.4M
CNSPCNS Pharmaceuticals Inc
US$ 0.1415
(31.26%)
480.49M
MGOLMGO Global Inc
US$ 0.7176
(-15.08%)
411.17M
SRMSRM Entertainment Inc
US$ 0.6999
(95.50%)
248.48M
INTCIntel Corporation
US$ 23.60
(-2.20%)
225.04M
NVDANVIDIA Corporation
US$ 138.85
(2.63%)
189.56M

VERV Discussion

게시물 보기
Monksdream Monksdream 6 월 전
VERV new 52 week low
👍️0
Monksdream Monksdream 6 월 전
VERV new 52 week low
👍️0
Monksdream Monksdream 6 월 전
VERV 10Q due AUGUST5
👍️0
Monksdream Monksdream 8 월 전
VERV new 52 week low
👍️0
Monksdream Monksdream 8 월 전
VERV new 52 week low
👍️0
Monksdream Monksdream 9 월 전
VERV more new lows up ahead
👍️0
Monksdream Monksdream 9 월 전
VERV new 52 week low
👍️0
Monksdream Monksdream 10 월 전
VERV new 52 week low
👍️0
Monksdream Monksdream 10 월 전
VERV new 52 week low
👍️0
Monksdream Monksdream 10 월 전
VERV new 52 week low
👍️0
Monksdream Monksdream 10 월 전
VERV new 52 lo
👍️0
Firestorm22 Firestorm22 11 월 전
uh oh
👍️0
Monksdream Monksdream 11 월 전
VERV over $10
👍️0
fink fink 1 년 전
Looking for an entry now
👍️0
Terpi Terpi 1 년 전
Could see another nice move here is the 50 day holds into close.
👍️0
Monksdream Monksdream 1 년 전
VERV morning rally
👍️0
TheFinalCD TheFinalCD 2 년 전
https://cathiesark.com/
👍️0
crudeoil24 crudeoil24 3 년 전
VERV IS A GREAT $$$$$ OPPORTUNITY.
👍️0
crudeoil24 crudeoil24 3 년 전
Verve Therapeutics started at outperform with $48 stock price target at BMO Capital
👍️0
crudeoil24 crudeoil24 3 년 전
Verve Therapeutics, Inc. is a genetic medicines company, developing an approach to the care of cardiovascular disease (CVD) transforming treatment from chronic management to single-course gene editing medicines. The Company’s initial two programs target PCSK9 and ANGPTL3, respectively, genes that regulate levels of blood lipids. Its lead product candidate, VERVE-101, is designed to permanently turn off the PCSK9 gene in the liver. Reduction of PCSK9 protein in the blood improves the ability of the liver to clear LDL-C from the blood. VERVE-101 utilizes LNP-mediated delivery to target the liver and base editing technology to make a single base change at a specific site in the PCSK9 gene in order to disrupt PCSK9 protein production. It is advancing VERVE-101 initially for the treatment of heterozygous familial hypercholesterolemia. Its second program is designed to permanently turn off the ANGPTL3 gene in the liver. ANGPTL3 is a key regulator of cholesterol and triglyceride metabolism.
👍️0

최근 히스토리

Delayed Upgrade Clock